[Skip to Content]
[Skip to Content Landing]
August 18, 2004

Radiation Therapy and Androgen Suppression as Treatment for Clinically Localized Prostate Cancer: The New Standard?

Author Affiliations

Author Affiliations: Department of Radiation Oncology and Molecular Radiation Sciences, The Johns Hopkins University School of Medicine, Baltimore, Md.

JAMA. 2004;292(7):864-866. doi:10.1001/jama.292.7.864

One of every 6 men living in the United States will be diagnosed with prostate cancer at some point in his life.1 Although the likelihood of death from such a diagnosis is much less than 1 in 6, nearly 30 000 men will die from prostate cancer this year.1 Many men who die from this disease were originally diagnosed with clinically significant tumors, which were palpable, of an intermediate to high grade on review of the needle biopsy specimen, and/or associated with a serum prostate specific antigen (PSA) of more than 10 ng/mL.2,3 The 10-year disease-free survival following surgical or nonsurgical therapy for such men is frequently less than 50%.4